TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2694853

Group type: EXPERIMENTAL
Intervention: Improved disease‐free survival of poor‐prognosis subgroups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Better chemotherapy regimens and bone marrow transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shortening of therapy duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardization between staging systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variable application and interpretation of multivariate analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger patient numbers in clinical studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reliable in vitro tests of chemosensitivity and chemoresistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitation of residual leukemia after remission induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delivery of optimum therapy and supportive care
Number of subjects: 0
Study: 1107612

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (35%)
Number of subjects: 111
Study: 31811674

Group type: EXPERIMENTAL
Intervention: Nurse-led care intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 52
Study: 30388950

Group type: EXPERIMENTAL
Intervention: Guided mindfulness practice (daily using an audio CD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 28637246

Group type: EXPERIMENTAL
Intervention: Psilocybin (0.215 mg/kg p.o.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25887140

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 186
Study: 23743754

Group type: EXPERIMENTAL
Intervention: Virtual reality-based balance rehabilitation program (12 sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Betahistine and diet (Control group)
Number of subjects: 44
Study: 21088592

Group type: EXPERIMENTAL
Intervention: AEP-guided anaesthesia (group A)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 450
Study: 19741494

Group type: EXPERIMENTAL
Intervention: Phenylephrine (80 microg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Ephedrine (10 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oxytocin plus phenylephrine (80 microg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 43
Study: 16500392

Group type: EXPERIMENTAL
Intervention: Scheduled maintenance treatment with infliximab (3 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Episodic treatment with infliximab (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scheduled maintenance treatment with infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Episodic treatment with infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scheduled infliximab maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 15624081

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 11716203

Group type: EXPERIMENTAL
Intervention: 30 mg of prednisolone p.o. for 1 week
Number of subjects: 43

Group type: COMPARATOR
Intervention: 1600 microg of inhaled budesonide daily for 1 week
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 1600 microg of inhaled budesonide daily for 3 weeks (after initial treatment)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Correlation between deltaFEV1 and eosinophil markers after 4 weeks
Number of subjects: 43
Study: 9386066

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 152

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 152
Study: 7606644

Group type: EXPERIMENTAL
Intervention: Walking on a treadmill for 1.5 h at 40% of maximal oxygen uptake, starting 1.5 h after the meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Resting for 6 h after consuming the meal
Number of subjects: 12
Study: 2786735

Group type: EXPERIMENTAL
Intervention: Fresh whole blood (2 units)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Stored blood (2-5 days)
Number of subjects: 237
Study: 31859197

Group type: EXPERIMENTAL
Intervention: Mesotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous dexketoprofen (systemic therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 30854836

Group type: EXPERIMENTAL
Intervention: Guided implant surgery
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 7
Study: 29162181

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Institutional care
Number of subjects: 0
Study: 26716432

Group type: EXPERIMENTAL
Intervention: Icare tonometer (IT)
Number of subjects: 44
Study: 23332456

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH) 18, 36, or 54 mg/day
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 21654267

Group type: EXPERIMENTAL
Intervention: Febuxostat 20 mg/d for 7 days
Number of subjects: 29
Study: 18571625

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 25
Study: 16827030

Group type: EXPERIMENTAL
Intervention: SmartPrep
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional tungsten carbide bud bur
Number of subjects: 50
Study: 15569270

Group type: EXPERIMENTAL
Intervention: Inflaban (100 mg) suppository
Number of subjects: 20

Group type: COMPARATOR
Intervention: Voltaren (100 mg) suppository
Number of subjects: 20
Study: 10908215

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 40 microg TID, n=209
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo, n=213
Number of subjects: 549
Study: 9200380

Group type: EXPERIMENTAL
Intervention: rhG-CSF (10 microg/kg/d x 3 d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rhG-CSF
Number of subjects: 25
Study: 8295812

Group type: EXPERIMENTAL
Intervention: Clarithromycin (7.5 mg/kg twice daily for 7 to 10 days)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Amoxicillin (20 mg/kg twice daily for 7 to 10 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 79

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 79
Study: 3307635

Group type: EXPERIMENTAL
Intervention: CQ + PSK
Number of subjects: 0

Group type: COMPARATOR
Intervention: CQ
Number of subjects: 0
Study: 29438162

Group type: EXPERIMENTAL
Intervention: Serum insulin (highest vs. lowest quartile)
Number of subjects: 21103

Group type: EXPERIMENTAL
Intervention: Serum glucose (highest vs. lowest quartile)
Number of subjects: 21103

Group type: EXPERIMENTAL
Intervention: Serum glucose and insulin
Number of subjects: 21103
Study: 27840034

Group type: EXPERIMENTAL
Intervention: Ankle joint mobilization
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Plantar massage
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Calf stretching
Number of subjects: 59
Study: 26117922

Group type: EXPERIMENTAL
Intervention: Cardioxipin (10 mg/kg daily i/v droplet infusion)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cytoflavin (10 ml in 200 ml 0.9% sodium chloride solution daily i/v droplet infusion for 10 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no treatment with cytoflavin and cardioxipin)
Number of subjects: 56
Study: 23117749

Group type: EXPERIMENTAL
Intervention: Auricular transcutaneous electric nerve stimulation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 21738958

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (LN)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Portable system (PS)
Number of subjects: 16
Study: 18811802

Group type: EXPERIMENTAL
Intervention: MRI scan
Number of subjects: 37
Study: 16563208

Group type: EXPERIMENTAL
Intervention: Integrated assessment (care management with additional clinical assessment by old age psychiatrist or geriatrician)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care management assessment only
Number of subjects: 0
Study: 14672354

Group type: EXPERIMENTAL
Intervention: Calcitonin treatment (not specified dosage or duration)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No calcitonin treatment (control group)
Number of subjects: 33
Study: 10852316

Group type: EXPERIMENTAL
Intervention: Perioperative NSAIDs (medium-to-high-dose regimens)
Number of subjects: 4129

Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 4129

Group type: EXPERIMENTAL
Intervention: NSAID regimens
Number of subjects: 4129

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 4129
Study: 8603962

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 16
Study: 1349990

Group type: EXPERIMENTAL
Intervention: Community-based team (n = 48)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hospital-based service (n = 52)
Number of subjects: 100
Study: 6329769

Group type: EXPERIMENTAL
Intervention: Oxyphenonium bromide 3 X 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline 3 X 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theophylline 2 X 300 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31545671

Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.03 IU/mL felypressin (P + FP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 adrenaline (L + AD)
Number of subjects: 22
Study: 29723393

Group type: EXPERIMENTAL
Intervention: Bortezomib added to rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (BzR‐hyperCVAD)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Bortezomib added to rituximab, high‐dose methotrexate, and high‐dose cytarabine (BzR‐MA)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 95
Study: 26213242

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance (CO‐OP) intervention for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (regular activity for 10 weeks)
Number of subjects: 20
Study: 24658945

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection (group H + A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-intensity focused ultrasound treatment (group H)
Number of subjects: 40
Study: 23100167

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) tablet of mitiglinide and metformin (10 mg/500 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Individual formulations of mitiglinide and metformin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments (FDC and individual formulations)
Number of subjects: 24
Study: 20502695

Group type: EXPERIMENTAL
Intervention: E2 (EXP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 18
Study: 18846346

Group type: EXPERIMENTAL
Intervention: 0.4% carbomer gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1% carboxymethyl cellulose (CMC) containing artificial tears
Number of subjects: 60
Study: 16195074

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative education programs, home visits from an outpatient team (SG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional rehabilitation often augmented by a stay at a rehabilitation center (CG)
Number of subjects: 50
Study: 12056535

Group type: EXPERIMENTAL
Intervention: Sarf (Julphar, UAE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ciprobay (Bayer AG, Germany)
Number of subjects: 28
Study: 10387505

Group type: EXPERIMENTAL
Intervention: Tailored multimedia intervention (computer-based soap opera and interactive 'info-mercials')
Number of subjects: 378

Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 378
Study: 8839230

Group type: EXPERIMENTAL
Intervention: ITF 296 (0.1, 0.5, 1.0 microgram/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ITF 296 (2.0, 4.0, 6.0 micrograms/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ITF 296 (10, 20, 40, 80 micrograms/kg) by 1-min i.v. injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ITF 296 (80 micrograms/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ITF 296 (40 and 80 micrograms/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ITF 296
Number of subjects: 20
Study: 2202551

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (3.0 g/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Enteric-coated acetylsalicylic acid (3.0 g/day)
Number of subjects: 19
Study: 7069216

Group type: EXPERIMENTAL
Intervention: epicutaneous methyl prednisolone (MP) at 10‐4 molar concentration
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: epicutaneous methyl prednisolone (MP) at 10‐5 molar concentration
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: epicutaneous methyl prednisolone (MP) at 10‐6 molar concentration
Number of subjects: 54
Study: 31852438

Group type: EXPERIMENTAL
Intervention: CT guided TRFA (Xper CT and fluoroscopy)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard TRFA (fluoroscopy only)
Number of subjects: 78
Study: 28338566

Group type: EXPERIMENTAL
Intervention: Midazolam (0.06 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 μg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study: 25834684

Group type: EXPERIMENTAL
Intervention: Virtual simulation examination format (n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Traditional oral examination format (n=17)
Number of subjects: 35
Study: 24166470

Group type: EXPERIMENTAL
Intervention: Elective stenosis repair (treatment group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Stenosis correction according to guidelines (control group)
Number of subjects: 58
Study: 21480257

Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment and adjuvant radiotherapy
Number of subjects: 0
Study: 19691794

Group type: EXPERIMENTAL
Intervention: Prophylactic pancreatic stenting followed by needle-knife fistulotomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard methods of cannulation without pre-cutting methods
Number of subjects: 22
Study: 17556697

Group type: COMPARATOR
Intervention: Calcium plus 1100 IU vitamin D3/d (Ca + D)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Calcium alone (Ca-only)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1179
Study: 15579215

Group type: EXPERIMENTAL
Intervention: Nicotine administered by patch
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 11836042

Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CA) 10 mg/day
Number of subjects: 336

Group type: COMPARATOR
Intervention: Micronized progesterone (MP) 200 mg/day
Number of subjects: 336
Study: 9888411

Group type: EXPERIMENTAL
Intervention: Oral glutamine (7 g three times per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (7 g glycine three times per day)
Number of subjects: 14
Study: 7675605

Group type: EXPERIMENTAL
Intervention: Eyes focused midway between the ball and their feet (5 cm closer to their feet)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Eyes positioned directly over the ball
Number of subjects: 48
Study: 2130294

Group type: EXPERIMENTAL
Intervention: Cellulose acetate membrane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 12
Study: 540461

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31436371

Group type: EXPERIMENTAL
Intervention: HEV-related liver failure (HEV-LF) patients
Number of subjects: 809

Group type: COMPARATOR
Intervention: Patients with cirrhosis
Number of subjects: 809
Study: 27649777

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25274015

Group type: EXPERIMENTAL
Intervention: myDIDeA (Internet-delivered dietary intervention)
Number of subjects: 66
Study: 23799691

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weight loss ≥ 5% and improved glucose tolerance)
Number of subjects: 3880
Study: 21585330

Group type: EXPERIMENTAL
Intervention: 10mg of intravenous metoclopramide
Number of subjects: 93

Group type: COMPARATOR
Intervention: 1 g of intravenous paracetamol
Number of subjects: 93
Study: 19037910

Group type: EXPERIMENTAL
Intervention: General Nordic Questionnaire for Psychological and Social Factors at Work (QPS(Nordic))
Number of subjects: 3976
Study: 17915794

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 585

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study: 14551632

Group type: EXPERIMENTAL
Intervention: Dental health educator visits over a 2-year period to counsel mothers
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group (no dental health educator visits)
Number of subjects: 269
Study: 11098022

Group type: EXPERIMENTAL
Intervention: Microsurgical epididymal sperm aspiration (MESA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) with frozen-thawed epididymal spermatozoa
Number of subjects: 88
Study: 9010920

Group type: EXPERIMENTAL
Intervention: GLP-1 0.125 nmol/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 0.25 nmol/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1328367

Group type: EXPERIMENTAL
Intervention: Active intervention with physical exercise and dietary regulation (HI-A group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive follow-up (HI-P group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active intervention (NI-A group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active intervention (LI-A group)
Number of subjects: 0
Study: 3907039

Group type: EXPERIMENTAL
Intervention: Machine perfusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cold storage
Number of subjects: 29
Study: 31475367

Group type: EXPERIMENTAL
Intervention: Sildenafil (0.42-2.09 mg/kg enterally) in cohort 1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sildenafil (0.125 or 0.25 mg/kg IV) in cohort 2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Coadministration of fluconazole (n=4)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IV doses of 0.125, 0.5 and 1 mg/kg every 8 hours (in absence of fluconazole)
Number of subjects: 34
Study: 29489038

Group type: EXPERIMENTAL
Intervention: Internet intervention (deprexis)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 1004
Study: 26702863

Group type: EXPERIMENTAL
Intervention: Chester step test (CST)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Modified incremental step test (MIST)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (20 healthy volunteers)
Number of subjects: 77
Study: 24708672

Group type: EXPERIMENTAL
Intervention: Practice team-supported self-managed exposure programme with cognitive behaviour therapy-oriented psychoeducation and instructions in four manual-based appointments, plus ten protocol-based telephone contacts for symptom monitoring.
Number of subjects: 444

Group type: COMPARATOR
Intervention: Usual care from general practitioners.
Number of subjects: 444
Study: 22339845

Group type: EXPERIMENTAL
Intervention: Intervention to increase parent knowledge and involvement in infant pain management
Number of subjects: 0
Study: 20511029

Group type: EXPERIMENTAL
Intervention: Sequential Compression Device (SCD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no SCD)
Number of subjects: 50
Study: 18484692

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 15897420

Group type: EXPERIMENTAL
Intervention: LigaSure procedure (group A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional method (group B)
Number of subjects: 35
Study: 12821428

Group type: EXPERIMENTAL
Intervention: Group T (totally occluded LAD, retrograde filling)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group C (critical stenosis, antegrade filling)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 10227007

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEE) for 21 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral CEE for 21 days followed by 5 mg/day of medrogestone for 7 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 39
Study: 8683427

Group type: EXPERIMENTAL
Intervention: Role-play instructional set
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Best-effort instructional set
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standardized instruction (control)
Number of subjects: 90
Study: 1650303

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice formulations (specific formulations not detailed)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 192
Study: 6821809

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (Burroughs-Wellcome)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Bacillus Calmette-Guerin (BCG) (Tice)
Number of subjects: 116
Study: 29440218

Group type: EXPERIMENTAL
Intervention: Ramipril (active treatment group)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 336
Study: 27558421

Group type: EXPERIMENTAL
Intervention: Oral Preexposure Prophylaxis (PrEP) with tenofovir
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100